Braftovi

Oncology

ASCO 26: Three strong Pfizer phase 3s, with Johanna Bendell

Pharmaphorum caught up with Johanna Bendell, Pfizer’s chief development officer for oncology, to learn about what the company is bringing to ASCO.

News

ASCO 25: Braftovi shows "unprecedented" survival gain

Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in the BREAKWATER trial, setting up full FDA approval.

News

Pfizer builds on Braftovi bowel cancer OK with survival data

Pfizer's Braftovi - just approved by the FDA as a first-line treatment for colorectal cancer based on response data - also extends patient survival.

News

FDA approves flurry of drugs ahead of holiday season

The FDA has wrapped up a series of new approvals as 2024 draws to a close, with Novo Nordisk, Pfizer, Vertex, and Hikma among the beneficiaries.

News

NICE says yes to Braftovi combination for colorectal cancer

Two months after rejecting Pierre Fabre’s Braftovi for a rare form of metastatic colorectal cancer (mCRC), NICE has changed its mind, and now says the drug can be funded by the NHS in Engla

ASCO 26: Three strong Pfizer phase 3s, with Johanna Bendell

ASCO 25: Braftovi shows "unprecedented" survival gain

Pfizer builds on Braftovi bowel cancer OK with survival data

FDA approves flurry of drugs ahead of holiday season

NICE says yes to Braftovi combination for colorectal cancer

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

Braftovi

Editor's Picks